NSTEMI - Non-ST Segment Elevation MI Clinical Trial
— PRESC1SE-MIOfficial title:
PRospective Evaluation of the European Society of Cardiology 0/1-hour Algorithm's Safety and Efficacy for Triage of Patients With Suspected Myocardial Infarction (PRESC1SE-MI)
The PRESC1SE-MI study compares two algorithms for triage of patients presenting with chest pain and symptoms of heart attack (myocardial infarction) to the emergency department. Both algorithms are recommended by the European Society of Cardiology: the 0/3-hour algorithm and the 0/1-hour algorithm. Currently, most emergency departments worldwide use the 0/3-hour troponin algorithm. Cardiac troponin (cTn) is a heart-specific biomarker which indicates damage of the heart muscle and which increases after a heart attack. In the 0/3-hour algorithm, the amount of troponin in the bloodstream is measured with a high-sensitivity assay at admission and 3 hours thereafter. Likewise, the 0/1-hour algorithm means that the blood sample in which the troponin is measured is collected at admission and 1 hour later. Since recent clinical studies suggest that the 0/1-hour algorithm is superior to the 0/3-hour algorithm, many hospitals consider switching to the 0/1-hour algorithm. The aim of this study is to assess how feasible the time-saving 0/1-hour algorithm would be in reality and whether it provides the same accuracy and safety in the diagnosis of myocardial infarction as the current practice the 0/3-hour algorithm.
Status | Recruiting |
Enrollment | 52156 |
Est. completion date | September 30, 2025 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients aged 18 and above - Presentation with acute non-traumatic acute chest pain to the emergency department - Suspicion of acute myocardial infarction Exclusion Criteria: - Terminal kidney failure requiring dialysis - Cardiac arrest - Cardiogenic shock |
Country | Name | City | State |
---|---|---|---|
Australia | St Andrew's War Memorial Hospital Brisbane | Brisbane | |
Austria | Vienna General Hospital (AKH Wien) | Wien | |
Finland | University Central Hospital Helsinki | Helsinki | |
Greece | Attikon General Hospital Athens | Athens | |
Italy | Careggi University Hospital Florence | Florence | |
Italy | Azienda Ospedaliera San Giovanni Addolorata | Roma | |
Italy | Hospital Città della Salute e della Scienza di Torino | Torino | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Romania | Emergency Institute for Cardiovascular Diseases C.C. Iliescu | Bucharest | |
Spain | Hospital Clinic Barcelona | Barcelona | |
Spain | University Hospital October 12 Madrid | Madrid | |
Spain | University Hospital Ramon y Cajal | Madrid | |
Spain | Hospital Clínico Universitario Valencia | Valencia | |
Switzerland | Kantonsspital Aarau | Aarau | |
Switzerland | St. Claraspital | Basel | |
Switzerland | Kantonsspital Luzern | Luzern | |
Switzerland | University Hospital Zurich | Zürich | |
United Kingdom | Leicester Royal Infirmary | Leicester | |
United Kingdom | Royal London Hospital | London | |
United Kingdom | Royal Cornwall Hospitals Treliske | Truro | |
United States | Baylor St. Luke's Medical Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
United States, Australia, Austria, Finland, Greece, Italy, Korea, Republic of, Romania, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite of all-cause mortality or new AMI (type 1) occurring within 30 days of index presentation | Mortality rate and number of newly diagnosed AMI (type 1) in all enrolled patients | 30 days | |
Primary | Time from ED presentation to ED discharge or transfer | Length of stay in the ED measured in hours | 30 days | |
Secondary | Proportion of patients managed as outpatients | Number of patients who stay in hospital for index event less than 24 hours | 24 hours | |
Secondary | Readmission for suspected AMI within 30 days after index presentation | Number of patients who stay in hospital for a new suspected AMI more than 24 hours within 30 days of index presentation | 30 days | |
Secondary | All-cause mortality at 30 days in all patients | Number of deceased patients within 30 days after index presentation | 30 days | |
Secondary | All-cause mortality at 365 days in all patients | Number of deceased patients within 365 days after index presentation | 365 days | |
Secondary | New AMI (type1) at 30 days in all patients | Number of newly diagnosed AMI (type 1) in all patients within 30 days of index presentation | 30 days | |
Secondary | New AMI (type 1) at 365 days in all patients | Number of newly diagnosed AMI (type 1) in all patients within 365 days of index presentation | 365 days | |
Secondary | Composite of all-cause mortality or new AMI (type 1) at 365 days after index presentation | Mortality rate and number of newly diagnosed AMI (type 1) in all enrolled patients | 365 days | |
Secondary | Satisfaction of patients with their evaluation in the ED | Satisfaction will be measured on a numerical/visual analogue scale from 0-100%, the higher the score, the greater the satisfaction | 30 days | |
Secondary | Treatment costs in the ED | Costs of procedures performed in the ED will be calculated according to national remuneration systems | 365 days | |
Secondary | Length of stay in the ED | Length of stay from admission to the ED to discharge or transfer will be calculated according to national remuneration systems | 30 days | |
Secondary | Feasibility of the 0/1-hour algorithm | Feasibility defined as the percentage of patients in whom the "1h" blood draw is performed within 1h +/- 20 minutes from the "0h" blood draw | 80 minutes | |
Secondary | Effectiveness of rule-in | Effectiveness defined as the time from presentation to coronary angiography in patients ultimately diagnosed with AMI (type 1) | 30 days | |
Secondary | Effectiveness of rule-out | Effectiveness defined as time from presentation to discharge in patients ultimately diagnosed with non-cardiac disease | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04951856 -
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
|
Phase 4 | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Completed |
NCT04648306 -
Restore EF Observational Study
|
||
Recruiting |
NCT06095557 -
MCG Discovery Study in Emergency Departments
|
N/A | |
Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
Completed |
NCT03489603 -
Clinical and Economic Outcomes of High Sensitivity Troponin for no ST Elevation Myocardial Infarction in Patients With Chest Pain in Emergency Departments in Italy-An Observational Study
|
||
Recruiting |
NCT04140019 -
Early Cardiac Magnetic Resonance Imaging in Suspected Non-ST-Elevation Myocardial Infarction
|
||
Completed |
NCT04289012 -
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
|
N/A | |
Active, not recruiting |
NCT03052036 -
The British Heart Foundation SENIOR-RITA Trial
|
N/A | |
Completed |
NCT02983123 -
One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome
|
||
Completed |
NCT03943966 -
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
|
N/A | |
Completed |
NCT03677180 -
National Cardiogenic Shock Initiative
|
||
Completed |
NCT03507777 -
ILUMIEN IV: OPTIMAL PCI
|
N/A | |
Recruiting |
NCT03863327 -
EKG Criteria and Identification of Acute Coronary Occlusion
|
||
Completed |
NCT03461484 -
e-BioMatrix 6 Month DAPT France
|
||
Recruiting |
NCT03089450 -
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
|
N/A | |
Active, not recruiting |
NCT04090281 -
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
|
Phase 4 | |
Recruiting |
NCT03562572 -
FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease
|
N/A | |
Completed |
NCT03822377 -
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
|
Phase 3 | |
Recruiting |
NCT04002739 -
PRedictOrs, PHEnotypes and Timing of Obstructive Sleep Apnea in Acute Coronary Syndrome
|
N/A |